GenFleet Therapeutics (HKG: 2595) announced preliminary clinical data from its Phase Ia dose‑escalation study of investigational GFH276, an oral molecular‑glue Pan‑RAS inhibitor, in patients with pretreated RAS‑mutant solid tumors – results presented at the 2026 European Society for Medical Oncology (ESMO) Congress, including an objective response rate of 41.1 % in evaluable pancreatic ductal adenocarcinoma (PDAC) patients.
Clinical Milestone Snapshot
| Item | Detail |
|---|---|
| Company | GenFleet Therapeutics (HKG: 2595) |
| Asset | GFH276 – investigational oral molecular‑glue Pan‑RAS (ON) inhibitor |
| Study | Phase Ia dose‑escalation (NCT07198321) |
| Population | Pretreated RAS‑mutant solid tumors |
| Dose Range | 5–320 mg once daily |
| Major Tumor Types | PDAC, NSCLC, CRC |
| Congress | ESMO 2026 |
| Announcement Date | 26 October 2026 |
Drug Profile & Mechanism of Action
- Molecule: GFH276, an oral small‑molecule Pan‑RAS (ON) inhibitor employing a molecular‑glue modality.
- Tri‑Complex Mechanism: Works through a CypA–GFH276–RAS tri‑complex, stabilizing cyclophilin A–mediated engagement of the target protein.
- Breadth of Coverage: Targets the active forms of most wild‑type and mutant RAS protein subtypes – covering the most common KRAS mutants (G12C, G12D, G12V, etc.) as well as NRAS and HRAS isoforms.
- Resistance Overcoming Potential: Preclinical studies suggest that, compared with KRAS inhibitors that bind the switch II pocket (SIIP), GFH276 has the potential to overcome adaptive and acquired resistance limitations of existing agents.
Clinical Evidence – Phase Ia Dose‑Escalation Results
| Cohort | Evaluable Patients | Dose Range | ORR | RAS‑Naïve Subgroup |
|---|---|---|---|---|
| PDAC (overall) | 61 | 40–160 mg QD | 41.1 % | 43.1 % (no prior RAS‑targeted therapy) |
| NSCLC (overall) | 11 | 80–160 mg QD | 45.5 % | 55.6 % (no prior RAS‑targeted therapy) |
| CRC | Not disclosed | 5–320 mg QD (study‑wide) | Not disclosed in the announcement | – |
The Phase Ia study (NCT07198321) enrolled patients across a broad range of RAS mutation subtypes, with major tumor types including pancreatic ductal adenocarcinoma (PDAC), non‑small cell lung cancer (NSCLC) and colorectal cancer (CRC), at dose levels from 5 to 320 mg once daily. As of the data cutoff, responses were observed in heavily pretreated patients – with numerically higher ORRs in those without prior RAS‑targeted therapy in both PDAC (43.1 %) and NSCLC (55.6 %).
Market Impact & Outlook
- Pan‑RAS Race: GFH276 positions GenFleet in the fast‑emerging Pan‑RAS inhibitor class, which aims to serve the full spectrum of RAS mutations rather than single alleles like G12C – addressing a substantially larger patient population across PDAC, NSCLC and CRC.
- PDAC Signal of Note: A 41.1 % ORR in evaluable, pretreated PDAC patients stands out given pancreatic cancer’s historically poor response rates to systemic therapy, marking GFH276 as a potential breakthrough candidate in one of oncology’s most difficult tumors.
- Differentiated Modality: The molecular‑glue tri‑complex mechanism and preclinical potential to overcome SIIP‑inhibitor resistance offer a differentiated scientific rationale versus first‑generation KRAS G12C drugs facing adaptive resistance in the clinic.
- Dose Optimization Ahead: With responses concentrated in the 40–160 mg QD range within a 5–320 mg escalation, further dose optimization in ongoing and future studies will be critical to maximizing the therapeutic index before pivotal development.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding GFH276, including ongoing clinical development, dose‑escalation and expansion results, regulatory timelines, and commercial potential. GFH276 remains investigational and has not been approved by any regulatory authority for any indication; preliminary Phase Ia results may not be replicated in larger studies, and actual outcomes may differ materially due to safety findings, confirmatory trial efficacy, regulatory review, and competitive dynamics in the RAS‑targeted therapy landscape.-Fineline Info & Tech
